Language:English
Language:

Xcessbio

Place your promotion here

You have no items in your shopping cart.

NLG919 (RG6078), IDO Inhibitor

NLG919 (RG6078), IDO Inhibitor

$129.00
A potent, selective and orally bioavailable IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor.
Catalog No. Unit Price Qty
M60258-2s 2 mg solid $129.00

Details

Product Information
Molecular Weight: 282.38
Formula: C18H22N2O
Purity: ≥98%
CAS#: 1402836-58-1
Solubility: DMSO up to 50 mM
Chemical Name: 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

NLG919 is a potent, selective and orally bioavailable IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki ~7 nM (EC50 ~75 nM) in vitro and in cell based assays. Oral administration of NLG919 reduces the [Kyn] in plasma and tissue by ~ 50%. Using human IDO+ pDCs in allogeneic MLR reactions, NLG919 potently blocked IDO- induced T cell suppression and restored robust T cell responses with an EC50 ~90 nM. NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I or pmel- 1) in vitro, (ED50 ~130 nM ) using mouse IDO+ pDCs from tumor-draining lymph nodes. In mice bearing large established B16F10 tumors, administration of NLG919 markedly enhanced the antitumor responses of naïve, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. Currently NLG919 is in phase I trial for the treatment of immunosuppression associated with cancer.

How to Use:

In vitro: NLG919 was used at 10 µM final concentration in various in vitro assays.
In vivo: NLG919 was dosed to mice orally or through IP injection with different dose and schedule.

Reference:

  • 1. Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. (2014) J Immunother Cancer. 2:21. 
  • 2. Mautino M, et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. (2013) AACR poster 491. 


NLG919_spec.pdf      
NLG919_MSDS.pdf      

Products are for research use only. Not for human use. 

Description

Details

Product Information
Molecular Weight: 282.38
Formula: C18H22N2O
Purity: ≥98%
CAS#: 1402836-58-1
Solubility: DMSO up to 50 mM
Chemical Name: 1-cyclohexyl-2-(5H-imidazo[5,1-a]isoindol-5-yl)ethan-1-ol
Storage: Powder: 4oC 1 year. DMSO: 4oC 3 month; -20oC 1 year.

Biological Activity:

NLG919 is a potent, selective and orally bioavailable IDO (indoleamine-(2,3)-dioxygenase) pathway inhibitor with Ki ~7 nM (EC50 ~75 nM) in vitro and in cell based assays. Oral administration of NLG919 reduces the [Kyn] in plasma and tissue by ~ 50%. Using human IDO+ pDCs in allogeneic MLR reactions, NLG919 potently blocked IDO- induced T cell suppression and restored robust T cell responses with an EC50 ~90 nM. NLG919 abrogated IDO-induced suppression of antigen-specific T cells (OT-I or pmel- 1) in vitro, (ED50 ~130 nM ) using mouse IDO+ pDCs from tumor-draining lymph nodes. In mice bearing large established B16F10 tumors, administration of NLG919 markedly enhanced the antitumor responses of naïve, resting pmel-1 cells to vaccination with cognate hgp100 peptide plus CpG-1826 in IFA. Currently NLG919 is in phase I trial for the treatment of immunosuppression associated with cancer.

How to Use:

In vitro: NLG919 was used at 10 µM final concentration in various in vitro assays.
In vivo: NLG919 was dosed to mice orally or through IP injection with different dose and schedule.

Reference:

  • 1. Li M, et al. The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma. (2014) J Immunother Cancer. 2:21. 
  • 2. Mautino M, et al. NLG919, a novel indoleamine-2,3-dioxygenase (IDO)-pathway inhibitor drug candidate for cancer therapy. (2013) AACR poster 491. 


NLG919_spec.pdf      
NLG919_MSDS.pdf      

Products are for research use only. Not for human use. 

Reviews

Write Your Review

How do you rate this product? *

Price:
Value:
Quality: